Skip to main content
Advertisement

< Back to Article

Fig 1.

BK generation reaction network including surface-mediated reactions.

FXII: factor FXII, αFXIIa: two-chain activated factor FXII, βFXIIa: single-chain activated FXII, FXI: factor FXI, PK: prekallikrein, PKa: kallikrein, HK: high molecular weight kininogen, cHK: cleaved high molecular weight kininogen, BK: bradykinin, α2M: α2-macroglobulin, C1inh: C1 esterase inhibitor. Surface-bound species are indicated by subscript ‘s’.

More »

Fig 1 Expand

Table 1.

List of biochemical reactions in the computational model of the kallikrein-kinin system.

Surface-bound species are indicated by subscript ‘s’, and solution-phase species are indicated by subscript ‘v’.

More »

Table 1 Expand

Fig 2.

Effect of DXS concentration on the rate of FXII activation.

More »

Fig 2 Expand

Fig 3.

FXII activation versus DXS concentration via two alternative FXII activation mechanisms.

Comparison of the Røjkjær and Schousboe [44] experimental data with simulations using optimised kinetic parameters for FXII activation, via either a combination of FXII autoactivation (reaction 3) and FXII self-activation (reaction 4), or just FXII self-activation in the presence of background αFXIIa.

More »

Fig 3 Expand

Fig 4.

Comparison of simulations of the activation of FXII, PK and cleavage of HK with the experimental data from Björkqvist et al [30].

a) [DXS] = 0.1 μg/ml, b) [DXS] = 1 μg/ml.

More »

Fig 4 Expand

Fig 5.

The level of BK generated by addition of 100 μg/mL DXS to plasma; comparison between in vitro data and model output.

In the LC-MS/MS assay, the BK level was tested at 10 different time points. The error bars represent the standard deviation of the BK levels in four tested plasma samples.

More »

Fig 5 Expand

Fig 6.

Model simulation comparison of BK generation in healthy and HAE plasma in the presence of 100 μg/ml DXS.

More »

Fig 6 Expand

Fig 7.

Inhibition of BK generation via different KKS inhibitors.

a) Simulated data showing the proportion of CSL312-FXII complex to total FXII in plasma equilibrated with different concentrations of CSL312, b) normalised BK concentrations generated by DXS-mediated activation of healthy pooled plasma titrated with various KKS inhibitors, comparison of in vitro data with model output. Experimental data was adapted from Cao et al. [8].

More »

Fig 7 Expand